ANI Pharmaceuticals, Inc.
210 Main Street West
Baudette
MN
United States
277 articles about ANI Pharmaceuticals, Inc.
-
ANI Pharmaceuticals Reports Fourth Quarter and Record Full-Year 2023 Financial Results and Provides 2024 Guidance
2/29/2024
ANI Pharmaceuticals, Inc. announced financial results and business highlights for the fourth quarter and full year ended December 31, 2023.
-
ANI Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
2/20/2024
ANI Pharmaceuticals, Inc. announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Leerink Partners Global Biopharma Conference in Miami Beach.
-
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024, at 8:30 a.m. ET
2/7/2024
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2023 financial results on Thursday, February 29, 2024, prior to the market open.
-
ANI Pharmaceuticals to Participate at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
1/29/2024
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference in New York City.
-
ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP
1/23/2024
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pentoxifylline Extended-Release (ER) Tablets, USP 400mg.
-
ANI Pharmaceuticals Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP
1/16/2024
ANI Pharmaceuticals, Inc. announced that it received U.S. Food and Drug Administration approval for the Abbreviated New Drug Application for Indomethacin Oral Suspension, USP.
-
ANI Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference
11/22/2023
ANI Pharmaceuticals, Inc. today announced that Nikhil Lalwani, President & CEO, will participate at the Piper Sandler 35th Annual Healthcare Conference in New York City as follows.
-
ANI Pharmaceuticals Reports Record Third Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance
11/8/2023
ANI Pharmaceuticals Reports Record Third Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance.
-
ANI Pharmaceuticals to Participate at Two Upcoming November 2023 Healthcare Conferences
10/30/2023
ANI Pharmaceuticals, Inc. announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will participate at two upcoming healthcare conferences as follows.
-
ANI Pharmaceuticals to Discuss Third Quarter 2023 Financial Results on November 8, 2023, at 8:30 a.m. ET
10/25/2023
ANI Pharmaceuticals, Inc. announced that the Company will release its third quarter 2023 financial results on Wednesday, November 8, 2023, prior to the market open.
-
ANI Pharmaceuticals Announces FDA Approval and Commercial Availability of New 1-mL Vial Size of Purified Cortrophin® Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares
10/2/2023
ANI Pharmaceuticals, Inc. announced U.S. Food and Drug Administration approval and commercial availability of a 1-mL vial of Purified Cortrophin® Gel .
-
ANI Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023
9/18/2023
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Cantor Global Healthcare Conference 2023 in New York City.
-
ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Tablets USP
9/12/2023
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Estradiol Tablets USP.
-
ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.1%
8/28/2023
ANI Pharmaceuticals, Inc. announced that it received U.S. Food and Drug Administration approval for the Abbreviated New Drug Application for Estradiol Gel, 0.1%.
-
ANI Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
8/24/2023
ANI Pharmaceuticals, Inc. announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference in New York City as follows.
-
ANI Pharmaceuticals Appoints Healthcare Executive Matthew J. Leonard to its Board of Directors
8/23/2023
ANI Pharmaceuticals, Inc. announced the addition of Matthew J. Leonard, R.Ph. to its Board of Directors.
-
ANI Pharmaceuticals Reports Record Second Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance
8/9/2023
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced business highlights and financial results for the three months ended June 30, 2023.
-
ANI Pharmaceuticals to Discuss Second Quarter 2023 Financial Results on August 9, 2023, at 8:30 a.m. ET
7/31/2023
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2023 financial results on Wednesday, August 9, 2023, prior to the market open.
-
ANI Pharmaceuticals to Present at the Jefferies Healthcare Conference
5/22/2023
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Jefferies Healthcare Conference in New York City. 8:30
-
ANI Pharmaceuticals Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
5/16/2023
ANI Pharmaceuticals, Inc. announced the closing of its previously announced underwritten public offering.